GHRP-2 Side Effects: A Diagnostic GH Secretagogue Used Off-Label
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue. It is approved in Japan as a diagnostic agent for the assessment of growth hormone deficiency. It is not approved by the FDA, EMA, or TGA as a therapeutic. Marketed off-label for body composition and anti-aging, those uses are not characterised by regulator review. WADA prohibits competitive use.
GHRP-2 is approved in some jurisdictions but not in others. Approved in Japan as a diagnostic GH-testing agent (single-dose). Not FDA-, EMA-, or TGA-approved as a therapeutic. WADA prohibits use in sport. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- GHRP-2 (pralmorelin) is approved in Japan as a diagnostic GH-testing agent, not as a therapeutic.
- Not FDA-, EMA-, or TGA-approved as a therapeutic.
- Stimulates GH release alongside cortisol, prolactin, and appetite effects.
- WADA prohibits GHRP-2 in competitive sport.
- Long-term repeated use is not characterised by regulator-reviewed safety data.
What is GHRP-2, and what is it marketed for?
Growth hormone-releasing peptide 2 (pralmorelin). GHRP-2 is a ghrelin/GHS-R agonist that stimulates pulsatile GH release. Published research describes effects on prolactin, ACTH/cortisol, and appetite, alongside GH-axis effects.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Cortisol and prolactin elevation | Modest increases reported in trials | Common to GH-secretagogues; greater than seen with selective secretagogues like ipamorelin |
| Appetite increase | Ghrelin receptor agonism raises appetite | Mechanistic effect |
| Fluid retention and joint discomfort | Common to GH-axis stimulation | Reported across GH-secretagogue trials |
| WADA prohibited | Listed under WADA prohibited substances (S2) | Use in competitive sport is prohibited |
| Long-term safety | Approved single-dose diagnostic use only; long-term repeated use is not characterised | Limited long-term data |
Taking GHRP-2 alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About GHRP-2
No. GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for growth hormone deficiency, but it is not FDA-, EMA-, or TGA-approved as a therapeutic.
Both are ghrelin/GHS-R agonists. GHRP-2 produces a larger increase in cortisol and prolactin than the more selective ipamorelin. Neither is FDA-approved for therapeutic use.
Yes. WADA prohibits GHRP-2.
Long-term repeated use of GHRP-2 outside the approved single-dose diagnostic indication is not characterised in regulator-reviewed safety data.
References
- Bowers CY. GH releasing peptides: structure and kinetics. J Pediatr Endocrinol Metab. 1993. Source.
- Smith RG et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.